Across TCGA pan-cancer cohorts, ARID2 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated ARID2 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher ARID2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARID2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.
THYM, MESO, and UCEC are the cancer types where ARID2 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.